Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of Carbetocin Nasal Spray for Hyperphagia in Prader-Willi Syndrome
NCT06420297Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of carbetocin in hyperphagia, sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events at 36 months. Started Mar 2024; status: terminated.
02
Drugs
carbetocin
03
Conditions
hyperphagia
Beyond the preview
Go deeper on NCT06420297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06420297.